American Association of Retired Persons (1997) Profile of Older Americans.
Angus D. Karpetz H. (1998) Pharmaceutical Policies in Canada. Pharmacoeconomics. 14 (Suppl. 1): 81-96.
Anis A. Wen Q. (1998) Price Regulation of Pharmaceuticals in Canada. Journal of Health Economics. 17:21-38.
Anon. (1999) Mail Order Drug Sales Leap 10 Percent. American Druggist. July: 1.
Anon. (1999) Relief for the Rx Blues. Consumer Reports. October: 38-46
Atherly A. (1999). The Effect of Medicare Supplemental Insurance on Medicare Expenditures. Department of Health Policy and Management. School of Public Health. Emory University. Atlanta. GA. Unpublished Paper.
Barents Group LLC. (1999) Factors Affecting the Growth of Prescription Drug Expenditures. National Institute for Health Care Management Research and Educational Foundation.
Berndt ER. Cockburn IM. Cocks DL. et al. (1998). Prescription Drug Prices for the Elderly. Monthly Labor Review September: 23-34.
Bettelheim A. (1999) Drugmakers Under Siege. CQ Researcher. 9(33): 753-776.
Bloom N. Van Reene J. (1999) Regulating Drug Prices: Where do we go from here? Institute for Fiscal Studies. L5, L6, D4. 19 (3): 321–342. London. England.
Bloor K. Freemantle N. (1996) Lessons from International Experience in Controlling Pharmaceutical Expenditure II: Influencing Doctors. British Medical Journal. 312(7045): 1525-1527.
Bloor K. Maynard A. Freemantle N. (1996) Lessons from International Experience in Controlling Pharmaceutical Expenditure III: Regulating Industry. British Medical Journal. 313 (7048): 33-35.
Burstall. M. (1997) The Management of the Cost and Utilization of Pharmaceuticals in the United Kingdom. Health Policy. 41 (Suppl): S27-S43.
Burstall M. Reuben B. Reuben A. (1999) Pricing and Reimbursement Regulation in Europe: An Update on the Industry Perspective. Drug Information Journal. 33: 669-688.
Call K. Dowd B. Feldman R. Maciejewski M. (1999) Selection Experiences in Medicare HMOs: Pre-Enrollment Expenditures. Health Care Financing Review. 20(4): 197-209.
Carroll NV. Miederhoff PA. Waters LW. (1996) Profitability, Third Party Reimbursement, and Access to Community Pharmacies. Clinical Therapeutics. 18 (4): 702, 703-715.
Cartwright WS. Hu TW. Huang LF. (1992). Impact of Varying Medigap Insurance Coverage on the Use of Medical Services of the Elderly. Applied Economics. 24: 529-539.
Center for Drug Evaluation and Research (CDER). (1998) Report to the Nation: Improving Public Health through Human Drugs. Food and Drug Administration. U.S. Department of Health and Human Services. Washington D.C.
Center for Drug Evaluation and Research (CDER). (1998) Approved Drug Products with Therapeutic Equivalence Evaluations. 18th ed. Food and Drug Administration. United States Department of Health and Human Services. US Government Printing Office. Washington DC.
CibaGeneva. (1996) Pharmacy Benefit report: 1996 Trends and Forecasts. CibaGeneva Pharmaceuticals. Summit. NJ.
Cohen K. (1995) Glossary. Principles and Practices of Managed Care Pharmacy. Foundation for Managed Care Pharmacy. Alexandria. VA.
Cohen RA. Bloom B. Simpson G. et al. (1997) Access to Health Care. Part 3: Older Adults. National Center for Health Statistics. Vital Health Statistics 10 (198).
Copeland D. (1999) Prescription Drugs: Issues of Cost, Coverage, and Quality. EBRI Issue Brief. 208.
Coulson NE. Stuart, BC. (1995) Insurance Choice and the Demand for Prescription Drugs. Southern Economic Journal. 61(4): 1146-1157.
Crystal S, Harman J, Sambamoorthi U, Johnson R, Kumar R. (2000) Out of Pocket
Health Care Costs Among Older Americans. Journal of Gerontology:
Social Sciences, In press.
Danis M. Biddle AK. Henderson G. Garrett JM. DeVellis RF. (1997) Older Medicare Enrollees' Choices for Insured Services. Journal of the American Geriatrics Society, 45(6): 688-94.
Danzon PM. (1997) Pharmaceutical Price Regulation: National Policies versus Global Interests. The AEI Press. Washington DC.
Danzon P. Kim J. (1998) International Price Comparisons for Pharmaceuticals: Measurement and Policy Issues. Pharmacoeconomics. 14 (Suppl. 1): 115-128.
Davis M. Poisal J. Chulis G. Zarabozo C. Cooper B. (1999) Prescription Drug Coverage, Utilization, and Spending Among Medicare Beneficiaries. Health Affairs. 18(1): 231-43.
Dickson M. (1992) The Pricing of Pharmaceuticals: An International Comparison. Clinical Therapeutics. 14 (4): 604-610.
Dickson. M, Redwood H. (1998) Pharmaceutical Reference Prices: How Do They Work in Practice? Pharmacoeconomics. 14(5): 471-479.
Drummond M. Jönsson B. Rutten F. (1997) The Role Of Economic Evaluation in the Pricing and Reimbursement of Medicines. Health Policy. 40: 199-215.
Earl-Slater A. (1997) A Study of Pharmaceutical Policies in the EU. Policy Studies. 18 (3/4): 251-267.
Hillman A. Pauly M. Escarce J. Rippley K. Gaynor M. Clouse J, Ross R. (1999) Financial Incentives and Drug Spending in Managed Care. Health Affairs. 18 (2): 189-200.
Ettner S. (1997) Adverse Selection and the Purchase of Medigap Insurance by the Elderly. Journal of Health Economics. 16: 543-562.
Families USA. (1999) Hard to Swallow: Rising Drug Prices for America’s Seniors. Publication No. 99-107. November.
Freemantle. N. Bloor. K. (1996) Lessons from International Experience In Controlling Pharmaceutical Expenditure I: Influencing Patients. British Medical Journal. 314(7044): 1469-1470.
Ganther JM. Kreling D. (1999) Effect of a Change in Third Party Reimbursement Rate on Prescription Gross Margin. Journal of the American Pharmaceutical Association. 39(3): 346-352.
Gardner T. (1986) Structuring Drug Benefits. In final report of APhA Commission on Third-party Programs.
Gebhart F. (1998) Annual Rx survey: The New Golden Age. Drug Topics. March 16: 71-83.
Generic Pharmaceutical Industry Association (GPIA). (1998) Facts and Figures. Washington, DC.
Gibson M. Brangan N. Gross D. et al. (1999) How Much Are Medicare Beneficiaries Paying Out-Of-Pocket For Prescription Drugs? Washington DC: AARP Public Policy Institute.
Glaser M. (1999) Boom year. Drug Topics April 5: 47-53.
Gluck ME. (1999) A Medicare Prescription Drug Benefit. National Academy of Social Insurance.
Gold M. et al. (1999) Medicare Managed Care: Preliminary Analysis of trends in Benefits and Premiums, 1997-1999. Mathematica Policy Research. Washington D.C.
Grabowski H. Mullins CD. (Aug 1997) Pharmacy Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions. Social Science Medicine. 45(4): 535-44.
Gross DJ. Alecxih L. Gibson MJ. Corea J. Caplan C. Brangan N. (1999) Out-of-Pocket Health Spending by Poor and Near-Poor Elderly Medicare Beneficiaries. Health Services Research, 34(1 Pt 2): 241-54.
Hamilton BH. (1999) HMO Selection and Medicare Costs: Bayesian MCMC Estimation of a Robust Panel Data Tobit Model with Survival. Health Economics and Econometrics. 8: 403-414.
Hejna Chester Pharmacy Networks: Origins, Functions and Future Directions. (1995) Principles and Practices of Managed Care Pharmacy. Foundation for Managed Care Pharmacy. Alexandria. VA: 119.
Hellinger F. (1995) Selection Bias in HMOs and PPOs: A Review of the Evidence. Inquiry. 32: 135-148.
Hensley S. (1999) Prescription Costs Harder to Swallow. Providers and Payers Get a Big Dose of Reality with Explosive Spending and Patient Demand for New Drugs. Modern Healthcare. 29(34): 30-4.
Hewitt Associates (1999) Retiree Health Coverage: Recent Trends and Employer Perspectives on Future Benefits. Menlo Park, CA: The Henry J. Kaiser Family Foundation.
Horn SD. Sharkey PD. Tracy DM. et al. (1996) Intended and Unintended Consequences of HMO Cost Containment Strategies: Results from the Managed Care Outcomes Project. American Journal of Managed Care. 2: 253-64.
Hurd MD. McGarry K. (1997). Medical Insurance and the Use of Health Care Services by the Elderly. Journal of Health Economics. 16: 129-154.
Jacobzone. S. (1999) How can Pharmaceutical Policy Reconcile Social Objectives and Industrial Efficiency? A View from the Recent Experience of OECD Countries. Organization for Economic Cooperation and Development (OECD). Paris France.
Johnson RE. Goodman MJ. Hornbrook MC. Eldredge MB. (1997) The Impact of Increasing Patient Prescription Drug Cost Sharing on Therapeutic Classes of Drugs Received and on The Health Status of Elderly HMO Members. Health Services Research.32(1):103-22.
Kane. N. (1997) Pharmaceutical Cost Containment and Innovation in the United States. Health Policy. 41(Suppl): S71-S89.
Laschober M. (1997) Health and Health Care of the Medicare Population: Data from the 1993 Medicare Current Beneficiary Survey. Rockville MD. Westat, Inc.
Laschober M. Olin G. (1996) Health and Health Care of the Medicare Population: Data from the 1992 Medicare Current Beneficiary Survey. Rockville MD. Westat, Inc.
Le Pen C. (1996) Drug Pricing and Reimbursement in France: Towards a New Model? Pharmacoeconomics. 10 (Suppl. 3): 26-36.
Lecomte T. Paris V. (1998) Controlling Drug Expenditures in France, Germany, and the United Kingdom. Économie et Statistique. 312-313: 109-124.
Lillard LA, Rogowski J. Kington R. (1997) Long-Term Determinants of Patterns of Health Insurance Coverage in the Medicare Population. The Gerontologist. 37(3): 314-323.
Lillard LA. Rogowski J. Kington R. (1999) Insurance Coverage for Prescription Drugs: Effects on Use and Expenditures in the Medicare Population. Medical Care. 37(9): 926-936.
Long S. (1994) Prescription Drugs and the Elderly: Issues and Options. Health Affairs. 13(2): 157-74.
Long S. Gordon N. (1989) Updated Estimates of Medicare's Catastrophic Drug Insurance Program. Congressional Budget Office (CBO). Washington D.C.
López-Casanovas G. Puig-Junoy. J. (1999) Review of the Literature On Reference Pricing. Working Paper. Research Center on Health and Economics. Department of Economics and Business. Universitat Pompeu Fabra. Barcelona Spain. February.
Lutchmie N. Mahil S. Smith T (1999) Evaluating Reference-Based Pricing: Initial Findings and Prospects. Canadian Medical Association Journal. 161(3): 286-288.
Lyles A. Palumbo FB. (1999) The Effect of Managed Care on Prescription Drug Costs and Benefits. Pharmacoeconomics. 15(2): 129-140.
McArdle F. Copock S. Yamamoto D. et al. (1999) Retiree Health Coverage: Recent Trends and Employer Perspectives on Future Benefits. The Henry J. Kaiser Family Foundation: Menlo Park, CA.
Manning WG. Newhouse JP. Duan N. et al. (1987). Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. The American Economic Review. 77 (3): 251-327.
Minority Staff Report. (1998) Prescription Drug Pricing in the United States: Drug Companies Profit at the Expense of Older Americans. Committee on Government Reform. United States House of Representatives. Washington DC.
National Pharmaceutical Council (NPC) (1998) Pharmaceutical Benefits Under State Medical Assistance Programs. NPC. Reston VA.
Novartis, (1999) Pharmacy Benefit Report Facts and Figures: 1999 Edition. Novartis Pharmaceutical Company. East Hanover NJ.
National Wholesale Druggists' Association (NWDA) (1999) Industry Profile and Health Care Fact Book. Addendum.
Office of Inspector General. (1997) Experiences of Health Maintenance Organizations with Pharmacy Benefit Management Companies. United States Department of Health and Human Services. Washington D.C. April. Report Number OEI-01-95-00110.
Olin G. Liu H. (1998) Health and Health Care of the Medicare Population: Data from the 1994 Medicare Current Beneficiary Survey. Rockville MD. Westat Inc.
Organization for Economic Co-operation and Development (OECD). (1998) Social and Health Policies in OECD: A Survey of Current Programmes and Recent Developments. Paris France.
Pauriche P. Rupprecht F. (1998) Pharmaceuticals in France: a Review of Current Trends. Économie et Statistique. 312-313:7-20.
Pharmaceutical Care Management Association (PMCA) (1999) Facts and Figures, 1999.
Pharmaceutical Research and Manufacturers Association. (PhRMA) (1999) Pharmaceutical Industry Profile 1999. Washington D.C.
Pharmaceutical Research and Manufacturers Association. (PhRMA) (1998) Pharmaceutical Industry Profile 1998. Washington D.C.
Pharmaceutical Research and Manufacturers Association. (PhRMA) (1995) PhRMA Facts: Current Drug Price Increase Below General Inflation: GAO Says Past Increases Much Lower Than Reported. June. (http://www.phrma.org)
Physician Payment Review Commission (PPRC) (1996). Annual Report to Congress. ProPAC. Washington D.C.
Poisal JA. et al. (2000) Medicare Beneficiaries And Drug Coverage. Health Affairs. (forthcoming).
Poisal JA. Murray LA. Chulis GS. Cooper BS. (1999) Prescription Drug Coverage and Spending for Medicare Beneficiaries. Health Care Financing Review. 20(3): 15-27.
Riley G. Tudor C. Chiang YP. et al. (1996) Health Status of Medicare Enrollees in HMOs and Fee-for-Service in 1994. Health Care Financing Review. 17(4): 65-76.
Rowgowski J. Lillard LA. Kington R. (1997) The Financial Burden of Prescription Drug Use Among Elderly Persons. Gerontologist, 37(4): 475-482.
Sager A. Socolar D. (1999) Affordable Medications for Americans: Problems, Causes and Solutions. Prescription Drug Task Force. United States House of Representatives. Washington D.C.
Sasich L. Torrey E. Wolfe S. (1999) International Comparison of Prices for Antidepressant and Antipsychotic Drugs. Public Citizen’s Health Research Group. Washington DC.
Schöffski O. (1996) Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany. Pharmacoeconomics. 10 (Suppl. 2): 37-47.
Schulman KA. Rubenstein LE. Abernathy DR. et al. (1996) The Effect of Pharmacy Benefit Managers: Is It Being Evaluated? Annals of Internal Medicine. 124: 906-13.
Schweitzer S. (1997) Pharmaceutical Economics and Policy. New York: Oxford University Press.
Smith H. (1975) Principles and Methods of Pharmacy Management. Lea and Febiger. Philadelphia PA.
Smith S. Freeland M. Heffler S. et al (1998) The Next Ten Years of Health Spending: What Does the Future Hold? Health Affairs. 17(5): 128-140.
Stuart B. Coulson NE. (1994) Use of Outpatient Drugs as Death Approaches. Health Care Financing Review. 15(3): 63-82.
Stuart B. Grana J. (1998) Ability to Pay and the Decision to Medicate. Medical Care. 36(2): 202-211.
Stuart B. Grana J.(1995) Are Prescribed and Over-the-Counter Medicines Economic Substitutes? A Study of the Effects of Health Insurance on Medicine Choices by the Elderly. Medical Care, 33(5): 487-501.
Stuart B. Shea D. Briesacher B. (2000) Prescription Drug Coverage For Medicare Beneficiaries: Coverage and Health Status Matter. The Commonwealth Fund. New York.
Stuart B. Zacker C. (1999) Who Bears the Burden of Medicaid Drug Copayment Policies? Health Affairs. 18(2): 201-12.
Towse A. (1996) The UK Pharmaceutical Market. Pharmacoeconomics. 10 (Suppl. 3): 14-25.
Ulrich V. Wille E. (1996). Healthcare Reform and Expenditure on Drugs: The German Situation. Pharmacoeconomics. 10(Suppl. 2): 81-88.
U.S. Department of Health, Education and Welfare. (1968) Task force on Prescription Drugs. Approaches to Drug Insurance Design: Background Papers. Washington, DC. Office of the Secretary of Health.
U.S. Department of Health and Human Services Office of Inspector General. (1997), Experience of Health Maintenance Organizations with Pharmacy Benefit Managment Companies. Washington, D.C. Government Document #OEI-01-95-00110.
U.S. General Accounting Office. (1992) Prescription Drugs: Companies Typically Charge More in the United States than in Canada. Washington D.C. Report Number GAO/HRD-92-110.
U.S. General Accounting Office. (1994) Prescription Drugs: Companies Typically Charge More in the United States than in the United Kingdom. Washington D.C. Report Number GAO/HEHS-94-29.
U.S. General Accounting Office. (1994) Prescription Drugs: Spending Controls in Four European Countries. Washington D.C. Report Number GAO/HEHS-94-30.
U.S. General Accounting Office. (1995) Pharmacy Benefit Managers, Early Results on Ventures with Drug Manufacturers. Washington D.C. Report Number GAO/HEHS-96-45.
U.S. General Accounting Office. (1996) Health, Education and Human Services Division, Pharmacy Benefit Managers, Early results on Ventures with Drug Manufacturers. Washington D.C. Report Number GAO-96-45.
U.S. General Accounting Office. (1997) Pharmacy Benefit Managers: FEHBP Plans Satisfied with Savings and Services, but Retail Pharmacies Have Concerns. Washington D.C. Report Number GAO/HEHS-97-47.
U.S. General Accounting Office. (1999) Prescription Drug Benefits - Implication for Beneficiaries of Medicare HMO Use of Formularies. Washington D.C. Report Number GAO/HEHS-99-166.
United State House of Representatives, Committee on Government Reform and Oversight, Minority Staff Report (1998) Prescription Drug Pricing in the United States: Drug Companies Profit at the Expense of Older Americans. Washington, D.C.
von der Schulenburg J. (1997) Management of Cost and Utilization of Pharmaceuticals in Germany. Health Policy. 41(Suppl): S45-S53.
von der Schulenburg J. Uber A. (1997) Current Issues in German Healthcare. Pharmacoeconomics. 12(5): 517-523.
Walser BL. Ross-Degnan D. Soumerai SB. (1996) Do Open Formularies Increase Access to Clinically Useful Drugs? Health Affairs. 15(3): 95-108.
Wolfe JR Goddeeris JH. (1991) Adverse Selection, Moral Hazard, and Wealth Effects in the Medigap Insurance Market. Journal of Health Economics. 10: 433-459.
Ya-Chen T. (1999). Effects of Insurance on Prescription Drug Use by ESRD Beneficiaries. Health Care Financing Review. 20(3): 39-54.
"intro.pdf" (pdf, 23.11Kb)
"C1.pdf" (pdf, 75.87Kb)
"c2.pdf" (pdf, 169.02Kb)
"c3.pdf" (pdf, 92Kb)
"future.pdf" (pdf, 12.41Kb)
"appena.PDF" (pdf, 149.34Kb)
"appenb.pdf" (pdf, 27Kb)